The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Lung Cancer, Nonsmall Cell
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
-
Atrium Health Levine Cancer, Charlotte, North Carolina, United States, 28204
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States, 27157
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Wake Forest University Health Sciences,
Kathryn Mileham, MD, PRINCIPAL_INVESTIGATOR, Atrium Health Levine Cancer
2035-09